Back to results
US 10,300,112 B2Granted
Transgenic ungulates expressing CTLA4-IG and uses thereof
AssigneeRevivicor, Inc.
InventorDavid Lee Ayares
Life of this patent
Estimating the term…
Abstract
The present invention provides ungulates, including pigs, expressing CTLA4-Ig, as well as tissue, organs, cells and cell lines derived from such animals. Such animals, tissues, organs and cells can be used in research and medical therapy, including xenotransplanation. In addition, methods are provided to prepare organs, tissues and cells expressing the CTLA4-Ig for use in xenotransplantation, and nucleic acid constructs and vectors useful therein.
Claims11
A method of reducing cell mediated rejection of xenotransplanted cells in a recipient, comprising xenotransplanting genetically modified porcine cells into the recipient wherein:
- (i) the cell mediated rejection of the genetically modified porcine cells is reduced without suppression of the recipient's normal immune function;
- (ii) the genetically modified cells lack expression of the alpha-1,3-galactosyltransferase (alpha-1,3-GT) gene and express a transgene encoding a porcine CTLA4 peptide fused to a human immunoglobulin peptide (pCTLA4-Ig);
- and
- (iii) the genetically modified cells are directly obtained from a genetically modified porcine animal that lacks expression of the alpha-1,3-GT gene and expresses the pCTLA4-Ig peptide by insertion of the pCTLA4-Ig transgene into the genome of the animal.
1 more element
Dependencies are inferred from the claim text.